Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9918728 | International Journal of Pharmaceutics | 2005 | 6 Pages |
Abstract
The aim of this work was to develop a formulation for Z-DEVD-FMK, a peptide which is a caspase inhibitor and has been used in experimental animal studies for a decade. Peptide loaded chitosan nanoparticles were obtained by ionotropic gelation process and Z-DEVD-FMK was quantified by an HPLC method. The influence of the initial peptide concentration on the nanoparticle characteristics and release behavior was evaluated. The CS nanoparticles have a particle diameter (Z-average) ranging from approximately 313-412Â nm and a positive zeta potential (20-28Â mV). The formulation with the initial peptide concentration of 400Â ng/ml provided the highest loading capacity (0.46%) and the highest extent of release (65% at 24Â h) suggesting the possibility to achieve a therapeutic dose. According to the data obtained, this chitosan-based nanotechnology opens new and interesting perspectives for anticaspase activity.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
YeÅim AktaÅ, Karine Andrieux, Maria Jose Alonso, Pilar Calvo, R. Neslihan Gürsoy, Patrick Couvreur, Yılmaz Ãapan,